Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
In Reply: Mr Stafford believes that Dr Hill
and colleagues'1 connections to, and relationships
with, the Australian Pharmaceutical Benefits Scheme brings their subsequent
analysis into question. He states that the authors failed to reveal their
involvement in these official government-sponsored analyses. In fact, a footnote
on the first page of their article reveals that 1 of the authors was from
the Pharmaceutical Evaluation Section, Pharmaceutical Benefits Branch, Department
of Health and Aged Care. Furthermore, it is clearly stated that "The database
of submissions and the committee reports were scrutinized by 2 of [the] authors
(S.R.H. and D.A.H.)." As was made clear in another footnote, the study received
financial support from the Commonwealth Department of Health and Aged Care.
We believe that this was full disclosure. We point out that only those involved
in the analyses could be in a position to conduct such an overview because
the individual analyses, under the secrecy provisions of the Australian National
Health Act, are kept confidential.
Rennie D, Luft HS. Problems in Pharmacoeconomic Analyses—Reply. JAMA. 2000;284(15):1922-1924. doi:10.1001/jama.284.15.1921